rawfin.tv
XORTX Therapeutics Narrows Net Loss Amid Clinical Progress
EarningsstocksAI Generated

XORTX Therapeutics Narrows Net Loss Amid Clinical Progress

By rawfin.tv Markets Desk||Updated |1 min read|AI-assisted · Methodology

XORTX Therapeutics (XRTX) reported a reduced net loss of US$2.66 million in 2025, driven by advancements in its late-stage clinical programs. Despite this operational improvement, the company's cash reserves experienced a decline during the period.

XRTXBiotechClinical TrialsEarningsPharmaceuticals

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks